[177Lu]Lu-DOTATOC was redistributed to tumors and organs within 1 day. The patient did not report any discomfort during or after hospitalization, and no side effects related to extravasation were observed. Quantitative SPECT/CT scans at the subsequent treatment cycle of the same patient were ...
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397(10276):797-804. doi:10.1016/S0140-6736(21)00237-3 PubMedGoogle ScholarCrossref 9. Hofman MS...
No serious nephritic or hepatic side effects were observed. Conclusion: This study demonstrated that a 2.12-GBq dose of (LuEB)-Lu-177-PSMA seems to be safe and adequate in tumor treatment. Further investigations with an increased number of patients are warranted.Zang, JieLiu, QingxingSui, ...
177治疗性放射性药物作为前列腺特异性膜抗原抑制剂(iPSMA),其中与杂环肼基烟酰胺(HYNIC)结合的1,4,7,10‑四氮杂环十二烷‑N,N,N”,N””‑四乙酸(DOTA)生成使构象异构体和分子内氢键的数量最小化的刚性化学结构,从而产生分子中的活性位点(Lys(Nal)‑NH‑CO‑NH‑Glu)对于PSMA蛋白的生物识别有...
177Lu-PSMA therapy was generally well-tolerated and most side effects mentioned in this study are CTCAE graded 1–2. One patient was not motivated to continue treatment due to cumulative (grade 1) side-effects, and one patient developed severe (grade 3) thrombocytopenia that caused discontinuation...
Pluvicto (Lutetium Lu 177 Vipivotide Tetraxetan) may treat, side effects, dosage, drug interactions, warnings, patient labeling, reviews, and related medications including drug comparison and health resources.
The objective of this study was to analyze the safety and efficacy of the (177)Lu-labeled DOTAGA-based prostate-specific membrane antigen (PSMA) ligand (177)Lu-DOTAGA-(I-y)fk(Sub-KuE) ((177)Lu-PSMA) in patients with metastatic castration-resistant prostate cancer (mCRPC). Fifty-six mCRP...
This study presents a case of RrDTC who was treated with 177Lu-DOTATATE and 177Lu-PSMA, presumably as a first report in this regard. 展开 关键词: Lu DOTATATE prostate-specific membrane antigen radioiodine-refractory differentiated thyroid cancer ...
177Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy and quality of life assessment MP Yadav,S Ballal,M Tripathi,... - Nucl Med Commun 被引量: 0发表: 2017年 Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA ...
摘要: Purpose Dosimetry is critical to achieve the optimal therapeutic effect of radioligand therapy (RLT) with limited side effects. Our aim was to perform image-based absorbed dose calculation for the new...关键词:Prostate cancer PSMA mCRPC Lutetium-177 Dosimetry Radioligand radiation therapy ...